Almac
is pleased to announce the doubling of analytical capacity at its 240,000 sq. ft. North American Headquarters. The facility, built on a 40 acre site in Souderton, PA, north of Philadelphia, and occupied since 2010, delivers full-service, integrated clinical packaging, drug supply management, and technology solutions to pharmaceutical and biotech clients. The facility boasts state of the art analytical labs, supplementing existing facilities in the UK.
The analytical labs provide support for clinical packaging operations as well as stand-alone analytical services and are equipped with the latest equipment, including HPLC, UPLC, GC, UV, IR, DSC, KF and others. The additional lab investment will continue to offer these services as well as polymorph and salt screening and solid form development.
In continuing its investment, the new lab will also be equipped with the latest bathless dissolution apparatus for rapid and efficient comparative dissolution studies. This provides maximum flexibility for developing, validating and running assay, dissolution and stability methods, further complementing the large capacity stability chambers which provide all the required ICH stability conditions.
The analytical facility complements Almac’s specialty capabilities, including biocatalysis, radiolabelling, and peptide and protein synthesis. These services are all part of Almac’s comprehensive drug development services, including API and drug product development and GMP manufacture.
Almac will be exhibiting at the forthcoming Informex trade show, 14 – 17 February at Booth 2001.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.